Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study
Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy of ACOU085 in patients with testicular cancer undergoing high-dose cisplatin-based chemotherapy regimens (cis-Pt ≥300 mg/m2).
Tübingen, Germany
Germ-cell testicular cancer is the most common cancer among young men, with incidence rates continuously increasing. With the introduction of cisplatin as a treatment option in the late 1970s, most men with metastatic testicular cancer are cured, with a 30–60 year life expectancy after treatment. Ototoxicity is a typical and severe side effect of cisplatin treatment and is a consequence of irreversible damage to the sensory cells in the inner ear, the so-called outer hair cells. While ototoxicity may have been an unavoidable trade-off for a cancer cure to date, clinical hearing loss comes with considerable negative impacts for survivors, including communication problems, heightened fatigue, reduced social interaction, and an increased long-term risk of developing dementia. In preclinical models, ACOU085 has demonstrated its significant potential to reduce cisplatin-induced hearing loss and preserve outer hair cells from ototoxicity.
In the double-blind, randomized PROHEAR-Study, patients with testicular cancer receive transtympanic injections of ACOU085 in one ear and a placebo in the contralateral ear prior to each chemotherapy cycle, as such each patient serves as his own control. The PROHEAR-Study is being conducted at major university clinics across Germany and has been formally endorsed by the Study Group of the German Society of Otorhinolaryngology (DSZ-HNO).
“The enrollment of the first patient into our ACOU085 Clinical Phase 2 program marks a further major milestone in our efforts to finally make acute and subacute forms of hearing loss treatable” said Dr. Tim Bölke, CEO and CMO of Acousia Therapeutics.
About Acousia Therapeutics GmbH
Acousia Therapeutics GmbH is a privately held, clinical-stage biotech company based in Tübingen, Germany. The company is dedicated to the identification of small molecules for the effective prevention and treatment of different hearing loss etiologies. Acousia is focused on the development of proprietary drug candidates, which are designed to affect the sensory outer hair cells (OHC) in the cochlea of the inner ear. The unique dual mode of action of its small-molecule Kv7.4 activators combines acute functional OHC enhancement and sustained OHC protection and aims to both enhance and preserve a patient’s natural hearing. Acousia Therapeutics develops drugs for both local and systemic administration.
Contact
Tim Boelke, M.D.
boelke@acousia.com
www.acousia.com
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
FEV Group: Generative AI accelerates homologation: FEV simplifies country-specific type approval processes10.7.2025 11:23:00 CEST | Press release
Aachen – Vehicle development doesn’t end with technical readiness: The road to global market launches is only complete once homologation has been successfully achieved. The increasing complexity of national regulations poses growing challenges to OEMs and suppliers. FEV addresses these with an innovative, AI-based approach: The company-wide used ‘FEV GenAI Hub’ significantly simplifies and accelerates the analysis of regulatory requirements across different global markets, offering time and cost savings that can provide customers with a decisive competitive edge.
Green: Innovation from Switzerland: New pump drive developed by Green’s Andrea Luigi Campomilla providing more efficiency in data center cooling8.7.2025 09:38:05 CEST | Press release
Andrea Luigi Campomilla, Green’s Chief Operating Officer and Chief Engineer, is commissioning a newly developed pump drive. The results are promising.
Intuitive Surgical Deutschland GmbH: Intuitive’s da Vinci 5 Surgical System Receives CE Mark2.7.2025 09:55:29 CEST | Press release
Fifth-generation da Vinci surgical system approved for use in Europe across multiple procedures
EUROJET signs contract to provide EJ200 Engines for the recent Italian Air Force Eurofighter Order of up to 24 Aircraft27.6.2025 16:25:57 CEST | Press release
Rome, Italy, Friday, 27th June 2025 EUROJET Turbo GmbH, the consortium behind the EJ200 engine that powers the Eurofighter Typhoon, has today signed a new contract with the NATO Eurofighter & Tornado Management Agency (NETMA). Under this agreement, EUROJET will deliver up to 54 new EJ200 engines to the Italian Air Force as part of the Eurofighter Tranche I replacement. A renaissance of interest in the programme, it follows hot on the heels of the Spanish Halcón II contract announced at the end of last year.
European Marketing Distribution: MANIELE TASCA TAKES OVER PRESIDENCY OF EUROPE'S LEADING TRADE ALLIANCE EMD27.6.2025 08:30:00 CEST | Press release
Top manager from Italy emphasises continued close partnership with industry Stephanie Lotter, Director at Globus in Germany, elected to the EMD Executive Board
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom